Current Report Filing (8-k)
01 Août 2018 - 1:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 1, 2018
INTELLIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
40 Erie Street, Suite 130
Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(857) 285-6200
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the
Form 8-K filing
is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under
the
Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant
to Rule 14d-2(b) under
the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant
to Rule 13e-4(c) under
the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of
the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 1, 2018, Intellia Therapeutics, Inc.
announced its financial results for the three and six months ended June 30, 2018 (the Press Release). The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report
on Form
8-K.
The information in this report furnished pursuant to Item 2.02 shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing
under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
99.1 Press release dated August 1, 2018
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
|
Date: August 1, 2018
|
|
|
|
By:
|
|
/s/ Graeme Bell
|
|
|
|
|
|
|
Graeme Bell
Executive Vice President and
Chief Financial Officer
|
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024